Former Solvay CEO moves to Selecta

Former Solvay CEO Werner Cautreels has taken the reins at Selecta Biosciences, a Watertown, MA-based developer of synthetic nanoparticle vaccines and immunotherapies. Cautreels was CEO at Solvay when the company was acquired by Abbott Labs for $6.6 billion earlier this year. Selecta is using self-assembled nanoparticles that can better resemble a virus, a process scientists believe can trigger a more potent immune response. The company announced earlier this year that it raised about...